Free Trial

bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Update

bioMérieux logo with Medical background

bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 118,300 shares, a decrease of 19.1% from the December 15th total of 146,200 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 1,183.0 days.

bioMérieux Stock Performance

Shares of bioMérieux stock remained flat at $110.92 during mid-day trading on Thursday. The company's 50 day simple moving average is $105.25 and its 200-day simple moving average is $108.70. bioMérieux has a 1 year low of $93.50 and a 1 year high of $122.52.

bioMérieux Company Profile

(Get Free Report)

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in bioMérieux Right Now?

Before you consider bioMérieux, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.

While bioMérieux currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines